Evidence map›Paper›PMID 42255439›Full record

ArticleFrontiers in endocrinology2026

Modulation of chemokine secretion and oxidative stress

Alessia Greco, Francesca Coperchini, Elena Franchi, Marco Denegri, Laura Croce, Marsida Teliti, Vincenzo Marotta, Flavia Magri, Giuseppina De Marco, Eleonora Ferrarini and 4 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alessia GrecoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Francesca CoperchiniDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Elena FranchiDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Marco DenegriUnit of Endocrinology and Metabolism, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pavia, Italy.
Laura CroceDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Marsida TelitiDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Vincenzo MarottaDepartment of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy.
Flavia MagriDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Giuseppina De MarcoDepartment of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa, Pisa, Italy.
Eleonora FerrariniDepartment of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa, Pisa, Italy.
Luisa PignataDepartment of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa, Pisa, Italy.
Patrizia AgrettiLaboratory of Chemistry and Endocrinology, University Hospital of Pisa, Pisa, Italy.
Massimo TonaccheraDepartment of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa, Pisa, Italy.
Mario RotondiDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Perchlorate, nitrate, and thiocyanate are thyroid disruptors. Emerging evidence suggests they may exert further effects independent of iodide uptake inhibition, influencing oxidative stress and thyroid tumour development. This study aimed to assess their effects on cell viability, proliferation, reactive oxygen species (ROS) production, and chemokine expression in normal human thyroid cells and thyroid cancer cell lines. Methods: Thyroid cells, both normal (NHT, in primary cultures) and cancer (TPC-1 and 8505C), were exposed to increasing concentrations of perchlorate, nitrate, or thiocyanate for 24 hours. Cell viability and proliferation were assessed in each cell type. Intracellular ROS production was measured using H Results: None of the three anions significantly affected viability in NHT or 8505C cells, whereas high-dose thiocyanate reduced viability in TPC-1 cells. Proliferative responses were modest and cell-type specific, occurring mainly at the highest concentrations tested. Perchlorate induced a biphasic increase in ROS production in NHT, while thiocyanate slightly reduced ROS levels in TPC-1 cells; no consistent effects were observed in 8505C cells. Thiocyanate consistently increased CXCL8 secretion in NHT and TPC-1 cells, with a concentration-dependent but non-monotonic pattern, whereas nitrate and perchlorate had minimal effects. CXCL10 protein was undetectable in all conditions, despite significant and cell-specific modulation of CXCL10 mRNA expression. Conclusions: Beyond their role as NIS inhibitors, perchlorate, nitrate and thiocyanate modulate oxidative stress and chemokine secretion in human thyroid cells. Thiocyanate promotes a pro-inflammatory phenotype, potentially favouring a tumour-promoting thyroid microenvironment.

Indexed as

ChemokinesNitratesOxidative StressPerchloratesThiocyanatesThyroid GlandThyroid NeoplasmsCell Line, TumorCell ProliferationCell SurvivalChemokine CXCL10HumansInterleukin-8Reactive Oxygen SpeciesChemokine CXCL10ChemokinesInterleukin-8NitratesperchloratePerchloratesReactive Oxygen SpeciesthiocyanateThiocyanatesCXCL10CXCL8nitrateperchlorateROSthiocyanatethyroid

Identifiers

PMID42255439
PMCPMC13236544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.